Analyst coverage

The analysts listed below are following Vernalis. Please note that any opinions, estimates or forecasts regarding Vernalis's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Vernalis or its management. Vernalis does not by its reference below or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations. Vernalis accepts no responsibility for the views of these or any other analysts.

 

Canaccord Genuity Limited (Nominated Advisor and Broker)  Howard Miller
Shore Capital (Joint Broker) Tara Raveendran
Edison Investment Research Lala Gregorek
N+1 Singer Jens Lindqvist
Stifel Max Herrmann
RX Securities Samir Devani
Panmure Gordon Julie Simmonds
Cantor Fitzgerald Brian White



Latest News

Servier and Vernalis plc announce achievement of 3 milestones in their oncology drug discovery collaboration

Servier and Vernalis plc are pleased to announce the achievement of two research milestones and one clinical milestone in their oncology drug discovery collaboration, triggering a total payment of €2 million to Vernalis.

 

Read more ...

At a glance

More information on Vernalis and its pipeline ...

FactsheetNov14 Company fact sheet

Comm thumbnail Explore the pipeline ...

Contact Vernalis

T: 0118 938 0000
F: 0118 938 0001

Contact information
Maps and directions
Contact form

To report SUSPECTED ADVERSE REACTIONS, contact Vernalis Therapeutics, Inc. at 1-855-705-9546 and drugsafety@propharmagroup.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch